Custom DNA vaccine targets Kids' brain tumors in early trial
NCT ID NCT03988283
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a personalized DNA vaccine for children and young adults (ages 12-25) with central nervous system tumors that have come back or not responded to treatment. The vaccine is made from each patient's unique tumor DNA to train the immune system to fight the cancer. The main goals are to see if the vaccine is safe and possible to create for each patient.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIFFUSE MIDLINE GLIOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Washington University School of Medicine
RECRUITINGSt Louis, Missouri, 63110, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can trained immune cells outsmart brain tumors?
- Could cutting a wider margin around brain tumors extend survival?
- Can a Tumor's genetic blueprint guide better treatment for kids with brain cancer?
- Can a 7-Week brain tumor treatment beat the standard 10-Week plan?
- Could an antiparasitic drug boost radiation against childhood brain tumors?
- Can a simple dye help surgeons see brain tumors in real time?